Thus, the ability of MEKi (and other drugs upstream of ERK, such as lapatinib) to increase the expression of ERα can be therapeutically exploited to render cancer cells sensitive to endocrine therapy, irrespective of their response to MEKi alone. The gene discussed is ESR1; the disease is cancer.